Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
ISSN: 2161-0495
Department of Medicine, Samariterbund, University of Vienna, Vienna, Austria
Research Article
Efficacy and Tolerability of Sotrovimab, Molnupiravir, and Nirmatrelvir/ Ritonavir for Non-Hospitalized Patients at High Risk for COVID-19: A Retrospective, Single-Center Analysis
Author(s): Victoria Kauer*, David Totschnig, Max Augustin, Ferdinand Waldenberger, Mario Karoly, Michelle Nägeli and Christoph Wenisch
Background: The use of outpatient antiviral treatment for high-risk patients with coronavirus disease 19 (COVID-19) is crucial in preventing the progression to severe COVID-19 and reducing hospitalization rates.
Objective: The main goal of this retrospective, single-center analysis was to assess the feasibility and potential clinical impact of an outpatient administration of various available antiviral agents including Sotrovimab (SOT), Nirmatrelvir/Ritonavir (N/R), and Molnupiravir (MOL) to COVID-19 patients at high risk for disease progression. In addition, hospital admission rates between groups, side effects and subjective treatment effects were assessed.
Methods: We conducted a retrospective analysis on 2606 outpatient individuals with mild to moderate COVID-19 at risk for disease progression, hospitalization,.. View More»
DOI:
10.35248/2161-0495.23.13.544